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Learning points:
•	 McKittrick–Wheelock syndrome (MWS) is typically characterised by the triad of pre-renal failure, electrolyte 
derangement and chronic diarrhoea resulting from a secretory colonic neoplasm.
•	 Hyperglycaemia and new-onset diabetes are rare clinical manifestations of MWS.
•	 Hyperaldosteronism and/or hypokalaemia may worsen glucose tolerance in MWS.
•	 Aggressive replacement of fluid and electrolytes is the mainstay of acute management, with definitive treatment 
and complete reversal of the metabolic abnormalities being achieved by endoscopic or surgical resection of the 
neoplasm.
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McKittrick–Wheelock syndrome (MWS) is a rare consequence of severe dehydration and electrolyte depletion due 
to mucinous diarrhoea secondary to a rectosigmoid villous adenoma. Reported cases of MWS commonly describe 
hypersecretion of mucinous diarrhoea in association with dehydration, hypokalaemia, hyponatraemia, hypochloraemia 
and pre-renal azotemia. Hyperglycaemia and diabetes are rarely reported manifestations of MWS. Herein we describe the 
case of a 59-year-old woman who presented with new-onset diabetes and severe electrolyte derangement due to a giant 
rectal villous adenoma. Subsequent endoscopic resection of the tumour cured her diabetes and normalised electrolytes. 
This case describes a rare cause of ‘curable diabetes’ and indicates hyperaldosteronism and/or whole-body potassium 
stores as important regulators of insulin secretion and glucose homeostasis.
Background
McKittrick–Wheelock syndrome (MWS) is a rare 
disorder characterised by severe fluid and electrolyte 
depletion secondary to mucous diarrhoea caused by 
large rectal tumours, most notably villous adenoma 
(1, 2, 3). Patients with MWS commonly present with 
diarrhoea, dehydration and symptoms associated with 
severe electrolyte depletion, particularly those related 
to hypokalaemia. Symptomatic hyperglycaemia and 
new-onset diabetes are very rare manifestations of 
MWS. Herein we report a rare case of MWS in a female 
patient with new-onset diabetes as the initial presentation.
Case presentation
A 59-year-old woman presented with a 1-week history 
of increasing lethargy, polyuria and polydipsia in 
the absence of acute weight loss. A review of systems 
was significant for diarrhoea that had subjectively 
B G Challis and others McKittrick–Wheelock 
syndrome and diabetes
ID: 16-0013; May 2016
DOI: 10.1530/EDM-16-0013
http://www.edmcasereports.com 2
resolved 1 week before presentation. The patient had 
no significant personal or family medical histories, and 
she took no regular medications. Clinical examination 
revealed a lean female (BMI 23.3 kg/m2) who was 
clinically dehydrated, normotensive (125/81 mmHg) 
and tachycardic (110 beats/min) with reduced power on 
dorsiflexion of the right ankle.
Investigation
Initial biochemical investigations revealed 
hyperglycaemia (plasma glucose 27.2 mmol/L) without 
acidosis or ketosis (blood ketones 0.2 mmol/L), elevated 
C-peptide (2019 pmol/L) and HbA1c (105 mmol/mol 
normal reference range (NR) 35–45)). Additional 
biochemical investigations revealed hypona traemia 
(117 mmol/L (NR: 135–145)), hypokalaemia (2.7 mmol/L 
(NR: 3.5–5.3) and renal impairment (creatinine 
124 µmol/L (NR: 62–115)) (Table 1). Anti-islet and anti-
GAD antibody titres were negative. Thyroid function, a 
short Synacthen test and haematological indices were 
normal. Electrocardiogram revealed sinus tachycardia 
and normal QTc interval.
A provisional diagnosis of type 2 diabetes with diabetic 
radiculopathy was made, and following intravenous 
rehydration with potassium-supplemented isotonic 
saline, basal-bolus insulin therapy (Novorapid–Levemir 
combination) was commenced (20 units daily).
On review, 3 weeks later, glycaemic control had improved 
with insulin therapy; however, electrolyte and renal 
derangement (sodium 124 mmol/L, potassium 3.3 mmol/L, 
creatinine 164 µmol/L) persisted despite oral sodium and 
potassium supplementation. At that time, paired serum and 
urine osmolalities were 282 and 493 mOsm/kg respectively, 
and spot urine sodium was 6.2 mmol/L.
Clinical examination revealed progressive neurology 
with reduced power on dorsiflexion elicited in both right 
and left ankles prompting urgent magnetic resonance 
imaging (MRI) of her lumbrosacral spine, and the result was 
normal. Immunoglobulins, vitamin B12, autoantibodies 
(antinuclear antibody (ANA), anti-neutrophil cytoplasmice 
antibody (ANCA), anti-extractable nuclear antigens 
(ENA), DNA, anti-centromere) and complement (C3, C4) 
levels were all within the normal range. When reviewed 
1 month later, however, the neurological and electrolyte 
abnormalities had completely resolved with stable 
capillary blood glucose measurements (6.0–11.0 mmol/L) 
achieved with progressively less total daily insulin that 
was eventually weaned completely.
Four months later, however, the patient re-presented 
with lethargy and pre-syncopal episodes associated 
with mucinous diarrhoea and weight loss. She had 
orthostatic hypotension and tachycardia (heart rate 
110 beats/min), but physical examination, including 
digital rectal examination, was otherwise unremark-
able. Laboratory investigations revealed hyponatraemia 
(112 mmol/L), hypokalaemia (2.6 mmol/L), hypergly-
caemia (13.8 mmol/L) and renal impairment (creatinine 
221 µmol/L; urea 41.4 mmol/L). Renin and aldoste-
rone levels were both profoundly elevated at 267 U/L 
(NR: 5.4–60) and 2676 pmol/L (NR: 100–450) respec-
tively. Fasting gut hormones were normal. The patient 




Initial presentation  
(0 week)




Follow up  
(post-resection; 20 weeks)
Follow up  
(36 weeks)
Sodium (mmol/L) 135–145 117 124 112 138 140
Potassium (mmol/L) 3.5–5.3 2.7 3.3 2.6 3.5 4.1
Creatinine (μmol/L) 62–115 124 164 221 84 83
Urea (mmol/L) 2.5–7.8 9.3 20.2 41.4 – 8.7
Bicarbonate (mmol/L) 21–32 28.5 21 22.8 – 29
Chloride (mmol/L) 95–106 – – 71 – –
Corrected calcium (mmol/L) 2.20–2.60 – 2.23 2.13 2.17 –
Phosphate (mmol/L) 0.80–1.50 – 1.27 1.45 0.92 –
Magnesium (mmol/L) 0.70–1.00 – 1.14 1.39 – –
Serum osmolality (mOsm/kg) 280–300 – 282 280 – –
Urine sodium (mmol/L) – 6.2 5.4 – –
Glucose (mmol/L) 27.2 11.5 13.8 5.8 –
HbA1c (mmol/mol) 35–45 105 – 63 – 45
C-peptide (pmol/L) 174–960 2019 – – – –
Renin (mU/L) 5.4–60 – – 267 – 24
Aldosterone (pmol/L) 100–450 – – 2676 – 351





responded to aggressive volume resuscitation with 
isotonic saline supplemented with potassium, and 
basal-bolus insulin was recommenced.
To further investigate diarrhoea and weight loss, 
abdominal computed tomography (CT) was performed to 
survey for occult malignancy; this revealed a large, soft 
tissue mass in a dilated rectum (Fig. 1). Subsequent MRI 
confirmed the presence of a polypoid mass, arising from 
the right lateral wall of the rectum with no evidence of 
adjacent adenopathy or local invasion. Full colonoscopy 
revealed a 10 cm hemicircumferential granular laterally 
spreading tumour, from which multiple biopsies were 
taken, arising 15 cm from the anal verge; the remaining 
colon was unremarkable. Histopathological examination 
diagnosed a tubulovillous adenoma with mainly 
moderate, low-grade dysplasia but focal high-grade 
dysplasia at the base of some villous formations with no 
features suggestive of a neuroendocrine neoplasm (Fig. 2).
Treatment
The patient underwent staged piecemeal endoscopic 
mucosal resection to debulk the polyp and followed by 
completion transanal endoscopic microsurgery (TEMS).
Outcome and follow-up
Following endoscopic resection of the villous adenoma, 
electrolytes, renal function and glycaemic control 
(HbA1c 45 mmol/L) have remained normal, and glucose-
lowering therapy is no longer required. Repeat endoscopic 
investigations revealed recurrence of the sessile polyp, 
which was managed with further endoscopic mucosal 
resection. To date, histopathological examination of 
all biopsied tissue has failed to identify the evidence of 
invasive malignancy or dysplasia. The patient remains 
under colonoscopic surveillance.
Discussion
Villous adenomas are neoplasms with malignant potential 
most commonly found in the rectum and rectosigmoid. 
The majority of patients with colonic adenomatous 
polyps are asymptomatic; however, larger polyps (>1 cm) 
may present with mild gastrointestinal symptoms or rectal 
bleeding. Rarely, large villous adenomas of the rectum 
or rectosigmoid cause secretory mucinous diarrhoea 
characterised by massive fluid loss, acute renal failure 
and electrolyte depletion due to the secretory capacity 
of the tumour coupled with minimal absorptive capacity 
of normal colonic mucosal due to reduced surface area 
distal to the adenoma. Hyperglycaemia and diabetes are 
rare manifestations of MWS, and to date, few cases of 
MWS in association with new-onset diabetes have been 
reported (4, 5, 6). In these reports, however, ascertaining 
whether hyperglycaemia was truly a manifestation of 
MWS is complicated by administration of high-dose 
glucocorticoids to affected subjects for possible adrenal 
insufficiency before hyperglycaemia was recognised. The 
case described herein provides a rare example of diabetes 
mellitus as the initial presenting feature of MWS in a 
glucocorticoid naïve patient.
Figure 1
CT of the pelvis demonstrates an 8 cm polypoid mass arising from the 
right lateral wall of the rectum. The tumour arises 15 cm from the anal 
verge, and abnormal mesorectal lymph nodes are absent. Appearances 
are in keeping with a villous adenoma.
Figure 2
Hematoxylin and eosin-stained photomicrograph shows a tubulovillous 
adenoma exhibiting moderate to low-grade dysplasia (10× 
magnification). Tumour invasion is not identified.
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In MWS, profound water and electrolyte derangement 
have been attributed to local tumoral secretion of 
prostaglandin E2 (PGE2) and/or cyclic mononucleotides. 
Indeed, indomethacin, an inhibitor of prostaglandin 
synthesis, has been shown to reduce rectal PGE2 and rectal 
fluid loss in patients with secretory villous adenomas 
(7). The mechanisms underlying glucose intolerance in 
MWS, however, remain unclear, although some evidence 
suggests that a causal association with hyperaldosteronism 
and/or total body potassium depletion may exist.
The renin–angiotensin–aldosterone system (RAAS) 
is normally activated in response to hyponatraemia 
and/or intravascular volume depletion, two of the 
recognised pathological consequences of MWS exhibited 
in the case we describe. Classically, aldosterone-induced 
mineralocorticoid receptor (MR) activation stimulates 
sodium reabsorption in the distal nephron, although 
extra-renal effects are increasingly appreciated, including 
those that contribute to worsening glucose tolerance.
In a seminal publication, Conn first described the 
association of hyperaldosteronism with both impaired 
glucose tolerance and impaired insulin response to 
oral glucose administration (8). Several studies have 
subsequently confirmed these metabolic abnormalities 
in subjects with aldosterone-producing adenomas, which 
normalised following adrenalectomy (9, 10). Analyses of 
several cardiovascular drug trials have provided further 
clinical evidence that pharmacological blockade of the 
RAAS has beneficial effects on glucose homeostasis (9) and 
significantly reduces the incidence of new-onset diabetes 
(11). To date, numerous mechanisms have been proposed 
to explain the diabetogenic actions of aldosterone, which 
include direct effects on glucose-stimulated insulin 
secretion, impairment of insulin sensitivity in adipocytes 
and skeletal muscle and reduction of circulating insulin-
sensitising adipokines such as adiponectin (12, 13, 14, 15). 
Collectively, these observations support the premise that 
in MWS, hyperaldosteronism, in response to profound 
fluid and sodium loss, may contribute to impaired glucose 
tolerance and explain the development of hyperglycaemia 
and diabetes mellitus seen in affected individuals. From 
the data presented here, however, we cannot exclude the 
possibility that the metabolic sequelae observed may, at 
least in part, be mediated through glucocorticoid receptor 
(GR) activation due to elevated plasma concentrations of 
aldosterone, a known GR agonist that does not normally 
display physiologically meaningful GR activity at normal 
plasma concentrations.
Hypokalaemia per se also has a diabetogenic effect 
and coexisting potassium depletion may confound 
interpretation of the aforementioned studies. Indeed, 
Conn originally implicated aldosterone-induced 
hypokalaemia as the cause of impaired glucose 
tolerance in patients with PA; however, restoration of 
normokalaemia by potassium supplementation only 
partially reversed the metabolic abnormality (8). That 
total body potassium status alone may influence glucose 
homeostasis was demonstrated in a recent study in 
which patients with primary aldosteronism were found 
to have potassium levels that negatively correlated with 
2 h plasma glucose levels in an oral glucose tolerance test 
(10). Moreover, thiazide-induced hypokalaemia results 
in diminished insulin secretion, and a meta-analysis 
of 29 studies involving 83 thiazide diuretic treatment 
arms found a significant correlation between the degree 
of diuretic-induced hypokalaemia and an increase in 
plasma glucose concentration (16). More recently, a 
randomised double-blind trial study has shown that 
the combination of amiloride, a potassium-sparing 
diuretic, with hydrochlorothiazide prevented glucose 
intolerance compared with treatment with either drug 
alone (17). Hypokalaemia has also been implicated as 
the cause of impaired glucose tolerance in Gitelman 
syndrome, an autosomal recessive renal tubulopathy 
characterised by hypokalaemic metabolic alkalosis, 
hypomagnesaemia, secondary hyperaldosteronism and 
normal blood pressure (18).
Potassium is an important intracellular cation that 
is involved in the transfer of high-energy phosphate 
required for ATP generation, which, in turn, promotes 
insulin secretion from pancreatic β-cells (8). Thus, 
hypokalaemia attenuates ATP generation, resulting in 
impaired insulin secretion, and several studies have 
demonstrated it to be of clinical significance in humans. 
For example, in healthy subjects rendered hypokalaemic 
and subjected to a glucose clamp, Rowe and colleagues 
found that potassium depletion was associated with 
impaired insulin secretion and did not impact upon 
tissue sensitivity (19). Similarly, β-cell responsiveness 
was diminished in subjects with thiazide-induced 
hypokalaemia compared with normokalemic subjects 
(20). Finally, in subjects with chronic hypokalaemia, 
biologically less active proinsulin-like components 
constitute a greater proportion of the total circulating 
insulin than in normokalemic subjects (21). Taken 
together, these observations support the notion that 
the diabetogenic effects of hypokalaemia are mediated 
through dysregulated insulin secretion and, in the context 
of MWS, may act in synergy with hyperaldosteronism to 
disrupt glucose homeostasis.





It is possible that other tumour-derived peptides 
may also contribute to the depletion syndrome and 
metabolic disturbances associated with MWS. For example, 
guanylin-related peptides, guanylin and uroguanylin, are 
poorly understood hormones that are secreted by the 
gastrointestinal tract, including goblet cells. In humans, 
they serve as potent regulators of intestinal salt and 
water homeostasis through activation of the guanylate 
cyclase C receptor (22). Similarly, insulin-like peptide 5 
(INSL-5), a gut-derived peptide, which has recently been 
implicated in energy and glucose homeostasis, is secreted 
by enteroendocrine cells of the gastrointestinal tract, with 
highest levels being detected within the colorectum (23). At 
present, reliable analytical reagents to quantify circulating 
levels of these peptide hormones are not available; however, 
it is tempting to speculate that peptides such as these may 
have causal roles in disorders characterised by secretory 
diarrhoea and metabolic disturbance, including MWS.
Untreated secretant villous adenoma leads to a 
mortality of 100% (24). Initial clinical management 
should involve aggressive fluid resuscitation and 
correction of electrolyte and metabolic disturbances. Once 
the patient is stable, more definitive therapies such as 
endocavitary irradiation, endoscopic resection or surgical 
removal should be considered. Endoscopic resection is 
the preferred method if the tumour is amenable to this 
approach, depending on the size and location of the 
tumour. When endoscopic resection is not possible, 
conventional surgery or TEMS may be considered. In cases 
such as the one we describe, endoscopic resection may 
be used to reduce tumour volume before proceeding to 
conventional surgery or TEMS.
Tumour resection and adequate hydro-electrolyte 
replacement should lead to complete recovery from MWS, 
except in situations where the sequelae of MWS remain 
irreversible, such as chronic renal failure or cardiac events 
secondary to intravascular depletion and electrolyte 
imbalance. Although rare, it is important to consider MWS 
as a possible diagnosis in patients with chronic diarrhoea 
as it is a curable condition and a missed diagnosis may 
lead to an adverse clinical outcome.
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